成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. Apoptosis Autophagy
  2. Caspase Autophagy Apoptosis
  3. PAC-1

PAC-1  (Synonyms: Procaspase activating compound 1)

目錄號(hào): HY-13523 純度: 99.93%
COA 產(chǎn)品使用指南 技術(shù)支持

PAC-1 是一種 procaspase-3 激活劑,誘導(dǎo)癌細(xì)胞凋亡,EC50 為 2.08 μM。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

我們將采用定制合成服務(wù)的方式為您快速提供所需產(chǎn)品和技術(shù)服務(wù)

PAC-1 Chemical Structure

PAC-1 Chemical Structure

CAS No. : 315183-21-2

1.  客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)(單位)同一產(chǎn)品試用裝僅限申領(lǐng)一次,同一機(jī)構(gòu)(單位)一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ¥302
In-stock
5 mg ¥275
In-stock
10 mg ¥500
In-stock
50 mg ¥1400
In-stock
100 mg ¥2500
In-stock
200 mg   詢(xún)價(jià)  
500 mg   詢(xún)價(jià)  

* Please select Quantity before adding items.

Customer Review

    PAC-1 purchased from MCE. Usage Cited in: Oncotarget. 2017 Feb 14;8(7):12311-12322.  [Abstract]

    NB4 cells are treated with 5 μM Z-10 or 50 μM PAC-1 for the indicated time, and the expression of PML-RARα and cleaved caspase3 is analyzed by western blot.
    • 生物活性

    • 實(shí)驗(yàn)參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    PAC-1 is a procaspase-3 activator that induces apoptosis in cancer cells with an EC50 of 2.08 μM.

    IC50 & Target[1]

    Procaspase-3

    2.08 μM (EC50)

    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A549 IC50
    2.51 μM
    Compound: PAC-1
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 25874341]
    B16-F10 IC50
    > 100 μM
    Compound: 1, PAC-1
    Activation of procaspase-3-mediated human B16-F10 cell death after 24 hrs by MTS/PMS assay
    Activation of procaspase-3-mediated human B16-F10 cell death after 24 hrs by MTS/PMS assay
    [PMID: 16936720]
    BT-549 IC50
    14.3 μM
    Compound: 19
    Cytotoxicity against Smac mimetic-resistant human BT549 cells assessed as growth inhibition after 24 hrs by CellTiter-Glo assay
    Cytotoxicity against Smac mimetic-resistant human BT549 cells assessed as growth inhibition after 24 hrs by CellTiter-Glo assay
    [PMID: 27578248]
    Cancer cell lines IC50
    0.003 μM
    Compound: 1, PAC-1
    Cytotoxicity against human colon cancer cells after 24 hrs by MTS/PMS assay
    Cytotoxicity against human colon cancer cells after 24 hrs by MTS/PMS assay
    [PMID: 16936720]
    Colon cell IC50
    5.02 μM
    Compound: 1, PAC-1
    Cytotoxicity against human colon cells after 24 hrs by MTS/PMS assay
    Cytotoxicity against human colon cells after 24 hrs by MTS/PMS assay
    [PMID: 16936720]
    EL4 IC50
    6.5 μM
    Compound: 1, PAC-1
    Cytotoxicity against mouse EL4 cells assessed as cell death after 72 hrs by sulforhodamine B assay
    Cytotoxicity against mouse EL4 cells assessed as cell death after 72 hrs by sulforhodamine B assay
    [PMID: 25856364]
    HL-60 IC50
    0.92 μM
    Compound: 1, PAC-1
    Activation of procaspase-3-mediated human HL60 cell death after 72 hrs by MTS/PMS assay
    Activation of procaspase-3-mediated human HL60 cell death after 72 hrs by MTS/PMS assay
    [PMID: 16936720]
    Hs-578T IC50
    > 100 μM
    Compound: 1, PAC-1
    Activation of procaspase-3-mediated human Hs 578T cell death after 24 hrs by MTS/PMS assay
    Activation of procaspase-3-mediated human Hs 578T cell death after 24 hrs by MTS/PMS assay
    [PMID: 16936720]
    HT-29 IC50
    0.83 μM
    Compound: 8; PAC-1
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    [PMID: 26897090]
    HT-29 IC50
    0.83 μM
    Compound: 7, PAC-1
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    [PMID: 23838381]
    HT-29 IC50
    0.97 μM
    Compound: 5, PAC-1
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 23059545]
    HT-29 IC50
    1.02 μM
    Compound: PAC-1
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    [PMID: 25874341]
    HT-29 IC50
    1.36 μM
    Compound: PAC-1
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    [PMID: 25171780]
    Jurkat IC50
    4.4 μM
    Compound: 1, PAC-1
    Cytotoxicity against human Jurkat cells assessed as cell death after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human Jurkat cells assessed as cell death after 72 hrs by sulforhodamine B assay
    [PMID: 25856364]
    MCF-10A IC50
    3.2 μM
    Compound: 1, PAC-1
    Activation of procaspase-3-mediated human MCF-10A cell death after 72 hrs by MTS/PMS assay
    Activation of procaspase-3-mediated human MCF-10A cell death after 72 hrs by MTS/PMS assay
    [PMID: 16936720]
    MCF7 IC50
    > 40 μM
    Compound: PAC-1
    Antiproliferative activity against human MCF7 cells after 24 hrs by CCK-8 assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by CCK-8 assay
    [PMID: 31015910]
    MCF7 IC50
    > 75 μM
    Compound: 1, PAC-1
    Activation of procaspase-3 in human MCF-7 cells assessed as cell death after 72 hrs
    Activation of procaspase-3 in human MCF-7 cells assessed as cell death after 72 hrs
    [PMID: 16936720]
    MDA-MB-231 IC50
    3.2 μM
    Compound: PAC-1
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    [PMID: 25874341]
    MDA-MB-231 IC50
    4.6 μM
    Compound: 8; PAC-1
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    [PMID: 26897090]
    MDA-MB-231 IC50
    4.6 μM
    Compound: 7, PAC-1
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    [PMID: 23838381]
    MDA-MB-231 IC50
    4.7 μM
    Compound: 19
    Cytotoxicity against Smac mimetic-sensitive human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by CellTiter-Glo assay
    Cytotoxicity against Smac mimetic-sensitive human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by CellTiter-Glo assay
    [PMID: 27578248]
    MDA-MB-231 IC50
    4.8 μM
    Compound: PAC-1
    Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by MTT assay
    [PMID: 25171780]
    MDA-MB-231 IC50
    6.11 μM
    Compound: 5, PAC-1
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 23059545]
    MDA-MB-453 IC50
    2 μM
    Compound: 19
    Cytotoxicity against Smac mimetic-resistant human MDA-MB-453 cells assessed as growth inhibition after 24 hrs by CellTiter-Glo assay
    Cytotoxicity against Smac mimetic-resistant human MDA-MB-453 cells assessed as growth inhibition after 24 hrs by CellTiter-Glo assay
    [PMID: 27578248]
    MKN-45 IC50
    0.82 μM
    Compound: 8; PAC-1
    Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
    Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
    [PMID: 26897090]
    MKN-45 IC50
    0.82 μM
    Compound: 7, PAC-1
    Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
    Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
    [PMID: 23838381]
    MKN-45 IC50
    2.61 μM
    Compound: PAC-1
    Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay
    [PMID: 25171780]
    NCI-H226 IC50
    0.35 μM
    Compound: 1, PAC-1
    Activation of procaspase-3-mediated human NCI-H226 cell death after 24 hrs by MTS/PMS assay
    Activation of procaspase-3-mediated human NCI-H226 cell death after 24 hrs by MTS/PMS assay
    [PMID: 16936720]
    NCI-H226 IC50
    1.02 μM
    Compound: PAC-1
    Antiproliferative activity against human NCI-H226 cells after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H226 cells after 72 hrs by MTT assay
    [PMID: 25171780]
    NCI-H460 IC50
    1.25 μM
    Compound: PAC-1
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    [PMID: 25874341]
    NCI-H460 IC50
    3.57 μM
    Compound: 5, PAC-1
    Cytotoxicity against human H460 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 23059545]
    PBL IC50
    123.81 μM
    Compound: 8; PAC-1
    Cytotoxicity against human PBL cells after 72 hrs by MTT assay
    Cytotoxicity against human PBL cells after 72 hrs by MTT assay
    [PMID: 26897090]
    PC-12 EC50
    122 μM
    Compound: 2, PAC-1
    Induction of apoptosis in rat PC12 cells after 24 hrs by trypan blue exclusion assay
    Induction of apoptosis in rat PC12 cells after 24 hrs by trypan blue exclusion assay
    [PMID: 23859779]
    SK-N-SH IC50
    3.06 μM
    Compound: PAC-1
    Antiproliferative activity against human SK-N-SH cells after 72 hrs by MTT assay
    Antiproliferative activity against human SK-N-SH cells after 72 hrs by MTT assay
    [PMID: 25171780]
    U-937 IC50
    10.2 μM
    Compound: 1, PAC-1
    Cytotoxicity against human U937 cells assessed as cell death after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human U937 cells assessed as cell death after 72 hrs by sulforhodamine B assay
    [PMID: 25856364]
    U-937 IC50
    4.8 μM
    Compound: 1, PAC-1
    Cytotoxicity against human U937 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human U937 cells after 72 hrs by sulforhodamine B assay
    [PMID: 19708658]
    U-937 IC50
    6 μM
    Compound: PAC-1
    Antiproliferative activity against human procaspase-3 over-expressing U937 cells after 24 hrs by CCK-8 assay
    Antiproliferative activity against human procaspase-3 over-expressing U937 cells after 24 hrs by CCK-8 assay
    [PMID: 31015910]
    UACC-62 IC50
    > 100 μM
    Compound: 1, PAC-1
    Activation of procaspase-3-mediated human UACC62 cell death after 24 hrs by MTS/PMS assay
    Activation of procaspase-3-mediated human UACC62 cell death after 24 hrs by MTS/PMS assay
    [PMID: 16936720]
    體外研究
    (In Vitro)

    PAC-1 激活 procaspase-3,EC50 為 2.08 μM。PAC-1 表現(xiàn)出增強(qiáng)的鋅螯合能力 (EC50= 7.08 μM)。PAC-1 誘導(dǎo)白血病細(xì)胞死亡,IC50 為 4.03 μM,這與其他研究者報(bào)道的值一致。PAC-1 處理還以濃度依賴(lài)性方式導(dǎo)致其他惡性細(xì)胞死亡,IC50 范圍為 4.03 至 53.44 μM。在 15 種惡性細(xì)胞系中,WF-210 的總體平均 IC50 為 0.88 mM,PAC-1 為 19.40 μM。相比之下,正常人細(xì)胞 (PBL、L-02、HUVEC 和 MCF 10A) 對(duì) WF-210 的敏感性比 PAC-1 低 2.6 倍 (平均 IC50=412.34 μM)? (平均 IC50=158.29 μM)[1]。
    Procaspase-activating compound-1 (PAC-1) 是發(fā)現(xiàn)的第一個(gè)直接 caspase 激活化合物。PAC-1 處理可上調(diào)多種細(xì)胞系中的 Ero1α,而 Ero1α 的沉默會(huì)顯著抑制 ER 中的鈣釋放和細(xì)胞死亡[2]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    體內(nèi)研究
    (In Vivo)

    為了評(píng)估 WF-210 對(duì)惡性腫瘤生長(zhǎng)的體內(nèi)影響,我們檢測(cè)了 WF-210 在小鼠 Hep3B 和 MDA-MB-435 異種移植模型中抑制腫瘤生長(zhǎng)的能力。這兩個(gè)細(xì)胞系以相對(duì)較高的水平表達(dá) procaspase-3。肝癌細(xì)胞 Hep3B 異種移植誘導(dǎo)的腫瘤可以發(fā)展并生長(zhǎng)到 100 mm3 大小,之后 WF-210 (2.5 mg/kg) 或 PAC-1 (5.0 mg/ kg) 每天通過(guò)靜脈內(nèi) (iv) 給藥,持續(xù)兩周。如圖所示,PAC-1 和 WF-210 均顯著抑制 Hep3B 腫瘤異種移植物的生長(zhǎng)[1]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    分子量

    392.49

    Formula

    C23H28N4O2

    CAS 號(hào)
    性狀

    固體

    顏色

    White to yellow

    中文名稱(chēng)

    半胱天冬酶原活化物1

    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.

    儲(chǔ)存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗(yàn): 

    DMSO 中的溶解度 : 50 mg/mL (127.39 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響,請(qǐng)使用新開(kāi)封的 DMSO)

    H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

    配制儲(chǔ)備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 2.5478 mL 12.7392 mL 25.4784 mL
    5 mM 0.5096 mL 2.5478 mL 5.0957 mL
    查看完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?年內(nèi)使用, -20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?年內(nèi)使用。

    • 摩爾計(jì)算器

    • 稀釋計(jì)算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動(dòng)物實(shí)驗(yàn):

    請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液,再依次添加助溶劑:
    ——為保證實(shí)驗(yàn)結(jié)果的可靠性,澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的工作液,建議您現(xiàn)用現(xiàn)配,當(dāng)天使用;
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比;如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的方式助溶

    • 方案 一

      請(qǐng)依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (6.37 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL(飽和度未知)的澄清溶液。

      1 mL 工作液為例,取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中,混合均勻;再向上述體系中加入 50 μL Tween-80,混合均勻;然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制:將 0.9 g 氯化鈉,溶解于 ddH?O 并定容至 100 mL,可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請(qǐng)依序添加每種溶劑: 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.5 mg/mL (6.37 mM); 懸濁液; 超聲助溶

      此方案可獲得 2.5 mg/mL的均勻懸濁液,懸濁液可用于口服和腹腔注射。

      1 mL 工作液為例,取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中,混合均勻。

      2 g SBE-β-CD(磺丁基醚 β-環(huán)糊精)粉末定容于 10 mL 的生理鹽水中,完全溶解至澄清透明。
    動(dòng)物溶解方案計(jì)算器
    請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息:

    給藥劑量

    mg/kg

    動(dòng)物的平均體重

    g

    每只動(dòng)物的給藥體積

    μL

    動(dòng)物數(shù)量

    由于實(shí)驗(yàn)過(guò)程有損耗,建議您多配一只動(dòng)物的量
    請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠,建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。
    方案所需 助溶劑 包括:DMSO, ,均可在 MCE 網(wǎng)站選購(gòu)。 ,Tween 80,均可在 MCE 網(wǎng)站選購(gòu)。
    計(jì)算結(jié)果
    工作液所需濃度 : mg/mL
    儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO(母液濃度為 mg/mL)。
    您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度,以下方案僅供參考,如有需要,請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
    動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液,加入 μL 。 μL ,混合均勻至澄清,再加 μL Tween 80,混合均勻至澄清,再加 μL 生理鹽水。
    連續(xù)給藥周期超過(guò)半月以上,請(qǐng)謹(jǐn)慎選擇該方案。
    請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài),從左到右依次添加助溶劑。您可采用超聲加熱 (超聲清洗儀,建議頻次 20-40 kHz),渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.93%

    參考文獻(xiàn)
    Kinase Assay
    [1]

    Various concentrations of WF-210 or PAC-1 are added to procaspase-3 in buffer containing 50 mM HEPES, 0.1% CHAPS, 10% glycerol, 100 mM NaCl, 0.1 mM EDTA, 10 mM DTT pH 7.4,and incubated for 12 h at 37°C. The final volume is 10 mL and the final concentration of procaspase-3 is 1 mM. Then 40 mL of the substrate Ac-DEVD-pNA (final concentration 0.4 mM) in buffer containing 50 mM HEPES pH 7.4, 100 mM NaCl, 10 mM DTT, 0.1 mM EDTA disodium salt, 0.10% CHAPS, 10% glycerol is added and the absorbance of the plate is read at 405 nm for a total of 1 h. The slope of the linear portion for each well is determined as the enzyme activity[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [1]

    Cell viability is measured using the MTT method or the Cell Titer-Glo luminescent assay. For the MTT assay, the cells (1×105 cells/mL) are seeded into 96- well culture plates. After overnight incubation, cells are treated with various concentrations of agents (PAC-1, WF-210 or other agents) for 24 or 72 h. Then 10 mL MTT solution (2.5 mg/mL in PBS) is added to each well, and the plates are incubated for an additional 4 h at 37°C. After centrifugation (2500 rpm, 10min), the medium containing MTT is aspirated, and100mL DMSO is added. The optical density of each well is measured at 570 nm with a Biotek Synergy HT Reader. The Cell Titer-Glo kit is used to determine the relative levels of intracellular ATP as a biomarker for live cells[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    Mice[1]
    To determine the in vivo anti-tumor activity of WF-210, viable human gallbladder cancer GBC-SD cells (5×106/100 mL PBS per mouse), human breast cancer MDA-MB-435 cells (1×107/100 mL PBS per mouse), human liver cancer Hep3B cells (5×106/100 mL PBS per mouse) and human breast cancer MCF-7 cells (1×107/100 mL PBS per mouse) are subcutaneously (s.c.) injected into the right flank of 7- to 8-week old male SCID mice or Balb/c nude mice. Cell numbers are confirmed by trypan blue staining prior to injection. Specially, MCF-7 xenograft mice are also administered with the hormone 17-beta-estradiol (3 mg/kg) on alternate days. When the average s.c. tumor volume reached 100 mm3, mice are randomly divided into various treatment and control groups (eight mice per group). Tumor size is measured once every two days with a caliper (calculated volume=shortest diameter2×longest diameter/2). Body weight, diet consumption and tumor size are recorded once every two days. After two or four weeks, mice are sacrificed and tumors are excised and stored at -80°C until further analysis.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    參考文獻(xiàn)

    完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?年內(nèi)使用, -20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?年內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.5478 mL 12.7392 mL 25.4784 mL 63.6959 mL
    5 mM 0.5096 mL 2.5478 mL 5.0957 mL 12.7392 mL
    10 mM 0.2548 mL 1.2739 mL 2.5478 mL 6.3696 mL
    15 mM 0.1699 mL 0.8493 mL 1.6986 mL 4.2464 mL
    20 mM 0.1274 mL 0.6370 mL 1.2739 mL 3.1848 mL
    25 mM 0.1019 mL 0.5096 mL 1.0191 mL 2.5478 mL
    30 mM 0.0849 mL 0.4246 mL 0.8493 mL 2.1232 mL
    40 mM 0.0637 mL 0.3185 mL 0.6370 mL 1.5924 mL
    50 mM 0.0510 mL 0.2548 mL 0.5096 mL 1.2739 mL
    60 mM 0.0425 mL 0.2123 mL 0.4246 mL 1.0616 mL
    80 mM 0.0318 mL 0.1592 mL 0.3185 mL 0.7962 mL
    100 mM 0.0255 mL 0.1274 mL 0.2548 mL 0.6370 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱(chēng):

     

    * 需求量:

    * 客戶姓名:

     

    * Email:

    * 電話:

     

    * 公司或機(jī)構(gòu)名稱(chēng):

       留言給我們:

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱(chēng):
    PAC-1
    目錄號(hào):
    HY-13523
    需求量: